Similar articles

• Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.

  Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS; Radiation Therapy Oncology Group 9413. Roach M 3rd, et al. J Clin Oncol. 2003 May 15;21(10):1904-11. doi: 10.1200/JCO.2003.05.004. J Clin Oncol. 2003. PMID: 12743142 Clinical Trial.
• Endocrine treatment of prostate cancer.

  Tammela T. Tammela T. J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31. J Steroid Biochem Mol Biol. 2004. PMID: 15663992 Review.
• Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer.

  Crook J, Ludgate C, Malone S, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G. Crook J, et al. Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):327-33. doi: 10.1016/j.ijrobp.2008.04.075. Epub 2008 Aug 15. Int J Radiat Oncol Biol Phys. 2009. PMID: 18707821 Clinical Trial.
• The role of intermittent androgen deprivation in prostate cancer.

  Boccon-Gibod L, Hammerer P, Madersbacher S, Mottet N, Prayer-Galetti T, Tunn U. Boccon-Gibod L, et al. BJU Int. 2007 Oct;100(4):738-43. doi: 10.1111/j.1464-410X.2007.07053.x. Epub 2007 Jul 23. BJU Int. 2007. PMID: 17662079 Review. No abstract available.
• Adjuvant medical therapy for prostate cancer.

  Sumey C, Flaig TW. Sumey C, et al. Expert Opin Pharmacother. 2011 Jan;12(1):73-84. doi: 10.1517/14656566.2010.516252. Epub 2010 Dec 1. Expert Opin Pharmacother. 2011. PMID: 21118060 Review.